Menu
Not yet recruiting NCT07337174

Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

Phase I Interventional Obesity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: HUC2-676, HUC2-676-R.
Who it may be relevant to
Registry conditions: Obesity. Basic parameters: 19 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized, Open-label, Single Dose, Two-way, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

Overview

The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.

Interventions

  • Drug HUC2-676
    subcutaneous injection
  • Drug HUC2-676-R
    subcutaneous injection

Primary outcome measures

  • Cmax following single-dose administration [Time frame: 0 through 72 hours post-dose]
  • AUC following single-dose administration [Time frame: 0 through 72 hours post-dose]

Eligibility criteria

Inclusion criteria

  • Healthy adult volunteers aged 19 to 65 years, inclusive, at screening.
  • Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period.

Exclusion criteria

  • Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders.
  • For females: Pregnant women (positive urine hCG) or nursing mothers.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07337174 · HUC2-676

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗